• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 184.71
Bid (Size) 180.03 (1)
Ask (Size) 189.93 (1)
Prev. Close 184.71
Today's Range 184.71 - 184.71
52wk Range 179.73 - 185.24
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
October 22, 2025
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
September 19, 2025
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+0.5%
+0.5%

More News

Read More
News headline image
A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts ↗
December 03, 2024
Via Benzinga
News headline image
Why Is BeiGene Stock Trading Higher On Wednesday? ↗
November 27, 2024
Via Benzinga
News headline image
Expert Outlook: BeiGene Through The Eyes Of 4 Analysts ↗
October 22, 2024
Via Benzinga
News headline image
Why Summit Therapeutics Rocketed Double-Digits Today ↗
April 23, 2025
Via The Motley Fool
Topics World Trade
News headline image
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
March 31, 2025
From BeiGene, Ltd.
Via Business Wire
News headline image
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
December 27, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio? ↗
December 15, 2024
Via Benzinga
News headline image
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
December 12, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
December 09, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
December 04, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
December 02, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
November 27, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene to Present at Upcoming Investor Conferences
November 26, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
November 19, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
November 14, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
November 12, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene to Present at the Jefferies London Healthcare Conference
November 06, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
November 05, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Mourns Death of Beloved Board Member Donald Glazer
October 28, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
October 21, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
October 16, 2024
From BeiGene, Ltd.
Via Business Wire
News headline image
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio? ↗
October 06, 2024
Via Benzinga

Frequently Asked Questions

Is BeiGene, Ltd. - American Depositary Shares publicly traded?
Yes, BeiGene, Ltd. - American Depositary Shares is publicly traded.
What exchange does BeiGene, Ltd. - American Depositary Shares trade on?
BeiGene, Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeiGene, Ltd. - American Depositary Shares?
The ticker symbol for BeiGene, Ltd. - American Depositary Shares is BGNE on the Nasdaq Stock Market
What is the current price of BeiGene, Ltd. - American Depositary Shares?
The current price of BeiGene, Ltd. - American Depositary Shares is 184.71
When was BeiGene, Ltd. - American Depositary Shares last traded?
The last trade of BeiGene, Ltd. - American Depositary Shares was at 12/31/24 04:00 PM ET
What is the market capitalization of BeiGene, Ltd. - American Depositary Shares?
The market capitalization of BeiGene, Ltd. - American Depositary Shares is 223.70B
How many shares of BeiGene, Ltd. - American Depositary Shares are outstanding?
BeiGene, Ltd. - American Depositary Shares has 224B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap